Novavax, Inc. (NVAX)

Novavax, Inc. is trading at $7.89, down 2.23% on the session. The 50 day average sits at $8.53 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 49.6, which reads as neutral, and MACD is bullish crossover. Volume is below average.

The nearest support is around $7.15 with resistance near $8.09, so that band frames the current range. Average daily movement is roughly $0.34, or about 4.3% of the share price, which is what any stop placement has to allow for. The overall health score of 50 out of 100 combines a trend score of 28, momentum of 64 and a risk score of 65.

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.